Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price Expected to Rise, Morgan Stanley Analyst Says

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective boosted by analysts at Morgan Stanley from $275.00 to $284.00 in a report released on Friday,Benzinga reports. The brokerage presently has an "equal weight" rating on the biopharmaceutical company's stock. Morgan Stanley's target price points to a potential upside of 13.60% from the company's previous close.

Other equities analysts also recently issued reports about the company. Piper Sandler restated an "overweight" rating and set a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. TD Cowen raised their price target on Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the company a "buy" rating in a report on Monday, October 21st. HC Wainwright restated a "buy" rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 13th. StockNews.com downgraded Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, January 9th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $299.48.

Alnylam Pharmaceuticals Stock Down 2.5 %

ALNY traded down $6.45 during trading on Friday, reaching $250.00. The stock had a trading volume of 910,256 shares, compared to its average volume of 691,656. The stock's 50 day moving average is $253.96 and its two-hundred day moving average is $263.29. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a market capitalization of $32.25 billion, a price-to-earnings ratio of -95.42 and a beta of 0.35. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). As a group, analysts expect that Alnylam Pharmaceuticals will post -2.24 earnings per share for the current year.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares of the company's stock, valued at $4,381,357.86. The trade was a 8.79 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the transaction, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. The trade was a 10.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,356 shares of company stock valued at $22,498,551. Insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Jennison Associates LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $61,160,000. Strategic Financial Concepts LLC bought a new position in Alnylam Pharmaceuticals in the 4th quarter worth approximately $41,529,000. Los Angeles Capital Management LLC boosted its stake in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company's stock worth $37,684,000 after purchasing an additional 135,829 shares during the period. Assenagon Asset Management S.A. boosted its stake in Alnylam Pharmaceuticals by 13.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company's stock worth $4,687,000 after purchasing an additional 2,285 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. boosted its stake in Alnylam Pharmaceuticals by 3.0% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company's stock worth $67,464,000 after purchasing an additional 8,462 shares during the period. 92.97% of the stock is currently owned by institutional investors.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.